AstraZeneca: Imfinzi Trial Fails To Meet Endpoint In Early-stage Non-small Cell Lung Cancer

(RTTNews) - AstraZeneca (AZN.L, AZN) said high-level results from the ADJUVANT BR.31 Phase III trial, sponsored by the Canadian Cancer Trials Group, showed Imfinzi did not achieve statistical significance for the primary endpoint of disease-free survival versus placebo in early-stage non-small cell lung cancer after complete tumour resection in patients whose tumours express PD-L1 on 25% or more tumour cells. The safety profile for Imfinzi was consistent with its known safety profile.

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "We are disappointed in the ADJUVANT BR.31 results. We are committed to addressing the remaining unmet need in lung cancer through our broad development programme."

The company noted that Imfinzi is also being investigated as monotherapy and in combinations in several other early-stage lung cancer settings, including in medically inoperable or unresected Stage I-II NSCLC and unresectable, Stage III NSCLC.

For More Such Health News, visit

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.